International Journal of Inflammation / 2013 / Article / Tab 4

Clinical Study

Cost Effectiveness of TNF- Inhibitors in Rheumatoid Arthritis

Table 4

Resulting ICERs in terms of improvement by the DAS-28.

PatientsCost differences between Treatment A and BDifference in DAS-28 score between Treatment A and BICER per unit of improvement in the DAS-28 over 6 monthsICER per 10% improvement in the DAS-28 over 6 months

Patient 1€6,4513.72€1,734€1,630
Patient 2€5,2183.88€1,345€1,264
Patient 3€5,4443€1,815€1,706
Patient 4€6,4893.46€1,875€1,763
Patient 5€5,3021.79€2,962€2,784
Patient 6€6,5362.51€2,604€2,448
Patient 7€6,4763.25€1,993€1,873
Patient 8€4,8912.88€1,698€1,596
Patient 9€5,7052.16€2,641€2,483
Patient 10€6,5081.49€4,368€4,106
Patient 11€5,6491.89€2,989€2,810
Patient 12€6,3253.27€1,934€1,818
Patient 13€1,8022.01€897€843
Average€5,6002.71€2,220€2,087

The ICERs per unit improvement and per 10% improvement in the DAS-28 following 6 months of TNF-α inhibitor therapy.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.